Actos News

More than 6,000 Actos bladder cancer lawsuits filed against manufacturer

September 26th, 2014

As of July 2014, more than 6,00 Actos bladder cancer lawsuits have been filed against drug manufacturer Takeda Pharmaceuticals and its U.S. distribution partner Eli Lily, according to the Takeda. The lawsuits allege that type 2 diabetes medication Actos caused patients’ bladder cancer after using the drug for at least one year. More »

Jury hearing arguments in Actos bladder cancer lawsuit

April 23rd, 2013

The first Actos bladder cancer lawsuit trial is underway in California, where a jury is hearing arguments from a patient who developed bladder cancer after using the diabetes medication. Jack Cooper took Actos for two years before developing bladder cancer. More »

Takeda to release successor to Actos

February 12th, 2013

Takeda Pharmaceuticals plans to release a successor to controversial type II diabetes drug Actos in mid- 2013. The drug, known by its medical name alogliptin, was previously twice denied approval by the Food and Drug Administration for insufficient health data concerning potential side effects. More »

Hissey Kientz publishes frequently asked questions for Actos bladder cancer

January 2nd, 2013

Hissey Kientz law firm has published a frequently asked questions section to provide more information about the diabetes medication Actos and bladder cancer to readers. The FAQs include information concerning who should not take Actos and certain risks associated with the drug. More »

Judge allows company to sell generic Actos

November 19th, 2012

A U.S. District Judge has allowed a company to begin immediately selling generic Actos, despite resistance from the Food and Drug Administration (FDA). Watson Pharmaceuticals will begin marketing the generic version of the top-selling type II diabetes drug Actos, which has come under fire for health concerns. More »

Actos doubles bladder cancer risk, British study finds

June 14th, 2012

A new study has confirmed that the diabetes medication Actos doubles the risk of developing bladder cancer among people who use the drug for at least two years. The Canadian study was published in the British Medical Journal (BMJ) and included more than 115,000 diabetes patients that were treated between 1988 and 2009. More »

Actos linked to higher bladder cancer risk, health agency says

May 4th, 2012

Health Canada—the country’s health regulator—has issued a statement warning that patients who used the type II diabetes drug Actos for more than one year are at an increased risk of bladder cancer. The agency is requiring manufacturer Takeda Pharmaceuticals to immediately update the drug’s label to reflect the increased risk. More »

Whistleblower claims Actos maker hid heart failure data

March 23rd, 2012

A whistleblower lawsuit has alleged that the manufacturer of the diabetes medication Actos failed to accurately report cases of heart failure associated with the drug to the Food and Drug Administration. Helen Ge’s Actos lawsuit alleges that Takeda Pharmaceuticals attempted to downplay risks associated with the drug by underreporting and misclassifying adverse side effects. More »

Illinois man files Actos bladder cancer lawsuit

January 17th, 2012

An Illinois man has filed an Actos bladder cancer lawsuit against the manufacturer of the diabetes drug. William Greenlee alleges in his lawsuit that Takeda Pharmaceuticals failed to properly warn patients of the increased risks of bladder cancer when taking Actos for more than a year. More »

Hissey Kientz Announces the Launch of Actos Bladder Cancer Legal Website

September 1st, 2011

The law firm of Hissey Kientz, LLP is announcing the launch of its new website, Actos Bladder Cancer Lawyers Help. The site will serve as a news and information resource for patients who have been affected by bladder cancer due to the use of Actos. More »

Page 1 of 212
I am currently represented by an attorney
*Required fields